Entera Bio Ltd. (ENTX) 10-Year Financial Performance & Capital Metrics

ENTX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Show more

Revenue $181K
EBITDA -$10M -7.4%
Net Income -$10M -7.3%
EPS (Diluted) -0.25 +19.4%
Gross Margin 4.97%
EBITDA Margin -5270.17%
Operating Margin -5295.58%
Net Margin -5271.27%
ROE -103.34% -28.7%
ROIC -
Debt/Equity 0.03 -10.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Sales declining 5.2% over 5 years
✗Shares diluted 29.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-5.17%

3Y-31.82%

TTM25.25%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM110.34%

ROCE

10Y Avg-56.27%

5Y Avg-89.58%

3Y Avg-85.54%

Latest-101.49%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	236K	365K	571K	134K	0	181K
Revenue Growth %	-	-	-	-	-0.53%	0.55%	0.56%	-0.77%	-1%	-
Cost of Goods Sold+	28K	35K	43K	0	448K	300K	373K	165K	56K	172K
COGS % of Revenue	-	-	-	-	1.9%	0.82%	0.65%	1.23%	-	0.95%
Gross Profit+	-28K	-35K	-43K	500K	-212K	65K	198K	-31K	-56K	9K
Gross Margin %	-	-	-	1%	-0.9%	0.18%	0.35%	-0.23%	-	0.05%
Gross Profit Growth %	-	-0.25%	-0.23%	12.63%	-1.42%	1.31%	2.05%	-1.16%	-0.81%	1.16%
Operating Expenses+	3.7M	5.37M	11.34M	11.36M	11.24M	11.23M	12.41M	13.04M	8.88M	9.59M
OpEx % of Revenue	-	-	-	22.72%	47.64%	30.78%	21.74%	97.29%	-	53.01%
Selling, General & Admin	1.59M	2.72M	8.57M	2.84M	4.28M	4.85M	5.69M	7.25M	4.43M	5.09M
SG&A % of Revenue	-	-	-	5.69%	18.14%	13.29%	9.96%	54.13%	-	28.15%
Research & Development	2.12M	2.65M	2.77M	8.52M	6.96M	6.38M	6.77M	5.78M	4.45M	4.5M
R&D % of Revenue	-	-	-	17.04%	29.5%	17.48%	11.86%	43.16%	-	24.86%
Other Operating Expenses	0	0	0	0	0	0	-46K	0	0	0
Operating Income+	-3.7M	-5.37M	11.34M	-10.86M	-11.45M	-11.17M	-12.22M	-13.07M	-8.94M	-9.59M
Operating Margin %	-	-	-	-21.72%	-48.53%	-30.6%	-21.4%	-97.52%	-	-52.96%
Operating Income Growth %	-	-0.45%	3.11%	-1.96%	-0.05%	0.02%	-0.09%	-0.07%	0.32%	-0.07%
EBITDA+	-3.67M	-5.33M	11.39M	-10.81M	-11.22M	-11.11M	-12.16M	-13M	-8.88M	-9.54M
EBITDA Margin %	-	-	-	-21.61%	-47.53%	-30.42%	-21.3%	-97.04%	-	-52.7%
EBITDA Growth %	-	-0.45%	3.14%	-1.95%	-0.04%	0.01%	-0.1%	-0.07%	0.32%	-0.07%
D&A (Non-Cash Add-back)	28K	35K	43K	54K	238K	63K	53K	64K	56K	46K
EBIT	-4.15M	-1.06M	-11.09M	-10.86M	-10.71M	-11.17M	-12.22M	-12.93M	-8.86M	-9.59M
Net Interest Income+	0	0	0	34K	-84K	-28K	-29K	83K	31K	58K
Interest Income	0	0	0	34K	0	0	0	83K	31K	58K
Interest Expense	0	0	0	0	84K	28K	29K	0	0	0
Other Income/Expense	-581K	4.17M	146K	557K	659K	-28K	-29K	134K	80K	58K
Pretax Income+	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.2M	-12.25M	-12.93M	-8.86M	-9.53M
Pretax Margin %	-	-	-	-20.61%	-45.74%	-30.67%	-21.45%	-96.52%	-	-52.64%
Income Tax+	0	0	-146K	0	0	20K	-59K	137K	29K	14K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.01%	1%	1%
Net Income+	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.22M	-12.19M	-13.07M	-8.89M	-9.54M
Net Margin %	-	-	-	-20.61%	-45.74%	-30.73%	-21.34%	-97.54%	-	-52.71%
Net Income Growth %	-	0.72%	-8.34%	0.08%	-0.05%	-0.04%	-0.09%	-0.07%	0.32%	-0.07%
Net Income (Continuing)	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.22M	-12.19M	-13.07M	-8.89M	-9.54M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.36	-0.10	-0.94	-1.29	-0.90	-0.54	-0.47	-0.45	-0.31	-0.25
EPS Growth %	-	0.72%	-8.4%	-0.37%	0.3%	0.4%	0.13%	0.04%	0.31%	0.19%
EPS (Basic)	-0.36	-0.14	-1.31	-0.91	-0.90	-0.54	-0.47	-0.45	-0.31	-0.25
Diluted Shares Outstanding	11.9M	11.9M	11.9M	11.51M	12.15M	18.42M	26.13M	28.81M	29.01M	37.65M
Basic Shares Outstanding	11.9M	8.57M	8.57M	11.37M	12.15M	18.42M	26.13M	28.81M	29.01M	37.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.9M	5.43M	12.42M	12.47M	15.64M	9.11M	25.33M	12.85M	11.26M	8.97M
Cash & Short-Term Investments	1.21M	4.16M	11.75M	11.52M	15.22M	8.59M	24.89M	12.31M	11.02M	8.66M
Cash Only	1.21M	4.16M	11.75M	7.51M	15.22M	8.59M	24.89M	12.31M	11.02M	8.66M
Short-Term Investments	0	0	0	4.01M	0	0	0	0	0	0
Accounts Receivable	0	0	0	725K	278K	255K	183K	246K	0	126K
Days Sales Outstanding	-	-	-	529.25	429.96	255	116.98	670.07	-	254.09
Inventory	0	0	0	130K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	160K	1.23M	182K	111K	97K	163K	254K	294K	238K	186K
Total Non-Current Assets+	847K	853K	861K	875K	1.07M	613K	658K	278K	508K	418K
Property, Plant & Equipment	193K	199K	207K	224K	462K	566K	395K	229K	488K	332K
Fixed Asset Turnover	-	-	-	2.23x	0.51x	0.64x	1.45x	0.59x	-	0.55x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	654K	654K	654K	651K	605K	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	80K
Other Non-Current Assets	0	0	0	0	0	47K	46K	6K	6K	6K
Total Assets+	2.75M	6.29M	13.28M	13.34M	16.7M	9.72M	25.99M	13.13M	11.77M	9.39M
Asset Turnover	-	-	-	0.04x	0.01x	0.04x	0.02x	0.01x	-	0.02x
Asset Growth %	-	1.29%	1.11%	0%	0.25%	-0.42%	1.67%	-0.49%	-0.1%	-0.2%
Total Current Liabilities+	804K	10.54M	2.02M	1.79M	4.59M	1.84M	3.16M	1.34M	1.09M	1.18M
Accounts Payable	351K	53K	596K	473K	334K	164K	166K	17K	83K	132K
Days Payables Outstanding	4.58K	552.71	5.06K	-	272.12	199.53	162.44	37.61	540.98	280.12
Short-Term Debt	0	9.88M	0	0	177K	189K	0	0	0	0
Deferred Revenue (Current)	0	0	0	225K	267K	158K	15K	0	0	0
Other Current Liabilities	210K	294K	995K	755K	3.24M	923K	455K	300K	500K	339K
Current Ratio	2.36x	0.52x	6.15x	6.97x	3.41x	4.95x	8.01x	9.58x	10.32x	7.63x
Quick Ratio	2.36x	0.52x	6.15x	6.90x	3.41x	4.95x	8.01x	9.58x	10.32x	7.63x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	27.63M	20.99M	42.82M	1.44M	192K	371K	261K	32K	288K	134K
Long-Term Debt	21.11M	15.87M	3.89M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	122K	243K	123K	0	256K	102K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.51M	5.12M	38.92M	1.44M	70K	128K	138K	32K	32K	32K
Total Liabilities	28.43M	31.53M	44.84M	3.23M	4.78M	2.21M	3.42M	1.37M	1.38M	1.31M
Total Debt+	8.05M	14.72M	3.89M	0	299K	432K	302K	91K	390K	272K
Net Debt	6.85M	10.56M	-7.85M	-7.51M	-14.92M	-8.16M	-24.59M	-12.22M	-10.63M	-8.39M
Debt / Equity	-	-	-	-	0.03x	0.06x	0.01x	0.01x	0.04x	0.03x
Debt / EBITDA	-	-	0.34x	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-0.69x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-136.36x	-398.86x	-421.28x	-	-	-
Total Equity+	-25.69M	-25.25M	-31.56M	10.12M	11.92M	7.51M	22.57M	11.75M	10.39M	8.08M
Equity Growth %	-	0.02%	-0.25%	1.32%	0.18%	-0.37%	2%	-0.48%	-0.12%	-0.22%
Book Value per Share	-2.16	-2.12	-2.65	0.88	0.98	0.41	0.86	0.41	0.36	0.21
Total Shareholders' Equity	-25.69M	-25.25M	-31.56M	10.12M	11.92M	7.51M	22.57M	11.75M	10.39M	8.08M
Common Stock	0	0	0	0	0	0	0	0	1K	1K
Retained Earnings	-29.42M	-30.62M	-41.81M	-52.12M	-62.91M	-70.24M	-82.43M	-95.5M	-104.39M	-113.93M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.4M	2.88M	7.4M	13.06M	11.44M	8.96M	41K	41K	41K	41K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.5M	-3.14M	-4.53M	-9.8M	-8.92M	-10.56M	-9.06M	-12.5M	-7.31M	-6.82M
Operating CF Margin %	-	-	-	-19.59%	-37.79%	-28.92%	-15.87%	-93.28%	-	-37.67%
Operating CF Growth %	-	0.1%	-0.44%	-1.16%	0.09%	-0.18%	0.14%	-0.38%	0.42%	0.07%
Net Income	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.22M	-12.19M	-13.07M	-8.89M	-9.54M
Depreciation & Amortization	28K	35K	43K	54K	238K	63K	53K	64K	56K	46K
Stock-Based Compensation	366K	1.49M	4.88M	1.23M	1.48M	901K	1.86M	0	1.69M	2.56M
Deferred Taxes	0	22K	-324K	-41K	33K	0	-217K	174K	29K	14K
Other Non-Cash Items	576K	-3.84M	1.16M	-232K	-569K	46K	18K	2.17M	0	-5K
Working Capital Changes	-183K	353K	909K	-506K	691K	-351K	1.41M	-1.83M	-195K	112K
Change in Receivables	0	0	0	-725K	447K	23K	72K	-63K	246K	-126K
Change in Inventory	0	0	0	117K	341K	0	-72K	0	0	0
Change in Payables	227K	-298K	543K	-123K	-139K	-147K	74K	-149K	66K	49K
Cash from Investing+	-54K	-1.12M	1M	-4.07M	3.95M	-53K	-17K	-102K	-17K	-3K
Capital Expenditures	-54K	-41K	-51K	-68K	-40K	-53K	-17K	-47K	-17K	-3K
CapEx % of Revenue	-	-	-	0.14%	0.17%	0.15%	0.03%	0.35%	-	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-1.07M	1.05M	-4M	3.99M	0	0	-55K	0	0
Cash from Financing+	4.46M	7.22M	11.11M	9.62M	12.65M	4.05M	25.38M	13K	6.04M	4.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	238K	204K	3.58M	0	-580K	516K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.55M	-3.18M	-4.58M	-9.86M	-8.96M	-10.61M	-9.08M	-12.55M	-7.33M	-6.82M
FCF Margin %	-	-	-	-19.73%	-37.96%	-29.07%	-15.9%	-93.63%	-	-37.69%
FCF Growth %	-	0.1%	-0.44%	-1.16%	0.09%	-0.18%	0.14%	-0.38%	0.42%	0.07%
FCF per Share	-0.30	-0.27	-0.38	-0.86	-0.74	-0.58	-0.35	-0.44	-0.25	-0.18
FCF Conversion (FCF/Net Income)	0.82x	2.62x	0.40x	0.95x	0.83x	0.94x	0.74x	0.96x	0.82x	0.71x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	89K	2K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-101.86%	-97.98%	-115.46%	-81.04%	-76.17%	-80.3%	-103.34%
Gross Margin	-	-	-	100%	-89.83%	17.81%	34.68%	-23.13%	-	4.97%
Net Margin	-	-	-	-2060.8%	-4574.15%	-3072.88%	-2134.33%	-9754.48%	-	-5271.27%
Debt / Equity	-	-	-	-	0.03x	0.06x	0.01x	0.01x	0.04x	0.03x
Interest Coverage	-	-	-	-	-136.36x	-398.86x	-421.28x	-	-	-
FCF Conversion	0.82x	2.62x	0.40x	0.95x	0.83x	0.94x	0.74x	0.96x	0.82x	0.71x
Revenue Growth	-	-	-	-	-52.8%	54.66%	56.44%	-76.53%	-100%	-

Frequently Asked Questions

Growth & Financials

Entera Bio Ltd. (ENTX) reported $0.1M in revenue for fiscal year 2024.

Entera Bio Ltd. (ENTX) grew revenue by 0.0% over the past year. Growth has been modest.

Entera Bio Ltd. (ENTX) reported a net loss of $10.8M for fiscal year 2024.

Dividend & Returns

Entera Bio Ltd. (ENTX) has a return on equity (ROE) of -103.3%. Negative ROE indicates the company is unprofitable.

Entera Bio Ltd. (ENTX) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Entera Bio Ltd. (ENTX) 10-Year Financial Performance & Capital Metrics

ENTX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $181K
EBITDA -$10M -7.4%
Net Income -$10M -7.3%
EPS (Diluted) -0.25 +19.4%
Gross Margin 4.97%
EBITDA Margin -5270.17%
Operating Margin -5295.58%
Net Margin -5271.27%
ROE -103.34% -28.7%
ROIC -
Debt/Equity 0.03 -10.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Sales declining 5.2% over 5 years
✗Shares diluted 29.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-5.17%

3Y-31.82%

TTM25.25%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-17.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM110.34%

ROCE

10Y Avg-56.27%

5Y Avg-89.58%

3Y Avg-85.54%

Latest-101.49%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	236K	365K	571K	134K	0	181K
Revenue Growth %	-	-	-	-	-0.53%	0.55%	0.56%	-0.77%	-1%	-
Cost of Goods Sold+	28K	35K	43K	0	448K	300K	373K	165K	56K	172K
COGS % of Revenue	-	-	-	-	1.9%	0.82%	0.65%	1.23%	-	0.95%
Gross Profit+	-28K	-35K	-43K	500K	-212K	65K	198K	-31K	-56K	9K
Gross Margin %	-	-	-	1%	-0.9%	0.18%	0.35%	-0.23%	-	0.05%
Gross Profit Growth %	-	-0.25%	-0.23%	12.63%	-1.42%	1.31%	2.05%	-1.16%	-0.81%	1.16%
Operating Expenses+	3.7M	5.37M	11.34M	11.36M	11.24M	11.23M	12.41M	13.04M	8.88M	9.59M
OpEx % of Revenue	-	-	-	22.72%	47.64%	30.78%	21.74%	97.29%	-	53.01%
Selling, General & Admin	1.59M	2.72M	8.57M	2.84M	4.28M	4.85M	5.69M	7.25M	4.43M	5.09M
SG&A % of Revenue	-	-	-	5.69%	18.14%	13.29%	9.96%	54.13%	-	28.15%
Research & Development	2.12M	2.65M	2.77M	8.52M	6.96M	6.38M	6.77M	5.78M	4.45M	4.5M
R&D % of Revenue	-	-	-	17.04%	29.5%	17.48%	11.86%	43.16%	-	24.86%
Other Operating Expenses	0	0	0	0	0	0	-46K	0	0	0
Operating Income+	-3.7M	-5.37M	11.34M	-10.86M	-11.45M	-11.17M	-12.22M	-13.07M	-8.94M	-9.59M
Operating Margin %	-	-	-	-21.72%	-48.53%	-30.6%	-21.4%	-97.52%	-	-52.96%
Operating Income Growth %	-	-0.45%	3.11%	-1.96%	-0.05%	0.02%	-0.09%	-0.07%	0.32%	-0.07%
EBITDA+	-3.67M	-5.33M	11.39M	-10.81M	-11.22M	-11.11M	-12.16M	-13M	-8.88M	-9.54M
EBITDA Margin %	-	-	-	-21.61%	-47.53%	-30.42%	-21.3%	-97.04%	-	-52.7%
EBITDA Growth %	-	-0.45%	3.14%	-1.95%	-0.04%	0.01%	-0.1%	-0.07%	0.32%	-0.07%
D&A (Non-Cash Add-back)	28K	35K	43K	54K	238K	63K	53K	64K	56K	46K
EBIT	-4.15M	-1.06M	-11.09M	-10.86M	-10.71M	-11.17M	-12.22M	-12.93M	-8.86M	-9.59M
Net Interest Income+	0	0	0	34K	-84K	-28K	-29K	83K	31K	58K
Interest Income	0	0	0	34K	0	0	0	83K	31K	58K
Interest Expense	0	0	0	0	84K	28K	29K	0	0	0
Other Income/Expense	-581K	4.17M	146K	557K	659K	-28K	-29K	134K	80K	58K
Pretax Income+	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.2M	-12.25M	-12.93M	-8.86M	-9.53M
Pretax Margin %	-	-	-	-20.61%	-45.74%	-30.67%	-21.45%	-96.52%	-	-52.64%
Income Tax+	0	0	-146K	0	0	20K	-59K	137K	29K	14K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.01%	1%	1%
Net Income+	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.22M	-12.19M	-13.07M	-8.89M	-9.54M
Net Margin %	-	-	-	-20.61%	-45.74%	-30.73%	-21.34%	-97.54%	-	-52.71%
Net Income Growth %	-	0.72%	-8.34%	0.08%	-0.05%	-0.04%	-0.09%	-0.07%	0.32%	-0.07%
Net Income (Continuing)	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.22M	-12.19M	-13.07M	-8.89M	-9.54M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.36	-0.10	-0.94	-1.29	-0.90	-0.54	-0.47	-0.45	-0.31	-0.25
EPS Growth %	-	0.72%	-8.4%	-0.37%	0.3%	0.4%	0.13%	0.04%	0.31%	0.19%
EPS (Basic)	-0.36	-0.14	-1.31	-0.91	-0.90	-0.54	-0.47	-0.45	-0.31	-0.25
Diluted Shares Outstanding	11.9M	11.9M	11.9M	11.51M	12.15M	18.42M	26.13M	28.81M	29.01M	37.65M
Basic Shares Outstanding	11.9M	8.57M	8.57M	11.37M	12.15M	18.42M	26.13M	28.81M	29.01M	37.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.9M	5.43M	12.42M	12.47M	15.64M	9.11M	25.33M	12.85M	11.26M	8.97M
Cash & Short-Term Investments	1.21M	4.16M	11.75M	11.52M	15.22M	8.59M	24.89M	12.31M	11.02M	8.66M
Cash Only	1.21M	4.16M	11.75M	7.51M	15.22M	8.59M	24.89M	12.31M	11.02M	8.66M
Short-Term Investments	0	0	0	4.01M	0	0	0	0	0	0
Accounts Receivable	0	0	0	725K	278K	255K	183K	246K	0	126K
Days Sales Outstanding	-	-	-	529.25	429.96	255	116.98	670.07	-	254.09
Inventory	0	0	0	130K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	160K	1.23M	182K	111K	97K	163K	254K	294K	238K	186K
Total Non-Current Assets+	847K	853K	861K	875K	1.07M	613K	658K	278K	508K	418K
Property, Plant & Equipment	193K	199K	207K	224K	462K	566K	395K	229K	488K	332K
Fixed Asset Turnover	-	-	-	2.23x	0.51x	0.64x	1.45x	0.59x	-	0.55x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	654K	654K	654K	651K	605K	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	80K
Other Non-Current Assets	0	0	0	0	0	47K	46K	6K	6K	6K
Total Assets+	2.75M	6.29M	13.28M	13.34M	16.7M	9.72M	25.99M	13.13M	11.77M	9.39M
Asset Turnover	-	-	-	0.04x	0.01x	0.04x	0.02x	0.01x	-	0.02x
Asset Growth %	-	1.29%	1.11%	0%	0.25%	-0.42%	1.67%	-0.49%	-0.1%	-0.2%
Total Current Liabilities+	804K	10.54M	2.02M	1.79M	4.59M	1.84M	3.16M	1.34M	1.09M	1.18M
Accounts Payable	351K	53K	596K	473K	334K	164K	166K	17K	83K	132K
Days Payables Outstanding	4.58K	552.71	5.06K	-	272.12	199.53	162.44	37.61	540.98	280.12
Short-Term Debt	0	9.88M	0	0	177K	189K	0	0	0	0
Deferred Revenue (Current)	0	0	0	225K	267K	158K	15K	0	0	0
Other Current Liabilities	210K	294K	995K	755K	3.24M	923K	455K	300K	500K	339K
Current Ratio	2.36x	0.52x	6.15x	6.97x	3.41x	4.95x	8.01x	9.58x	10.32x	7.63x
Quick Ratio	2.36x	0.52x	6.15x	6.90x	3.41x	4.95x	8.01x	9.58x	10.32x	7.63x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	27.63M	20.99M	42.82M	1.44M	192K	371K	261K	32K	288K	134K
Long-Term Debt	21.11M	15.87M	3.89M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	122K	243K	123K	0	256K	102K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.51M	5.12M	38.92M	1.44M	70K	128K	138K	32K	32K	32K
Total Liabilities	28.43M	31.53M	44.84M	3.23M	4.78M	2.21M	3.42M	1.37M	1.38M	1.31M
Total Debt+	8.05M	14.72M	3.89M	0	299K	432K	302K	91K	390K	272K
Net Debt	6.85M	10.56M	-7.85M	-7.51M	-14.92M	-8.16M	-24.59M	-12.22M	-10.63M	-8.39M
Debt / Equity	-	-	-	-	0.03x	0.06x	0.01x	0.01x	0.04x	0.03x
Debt / EBITDA	-	-	0.34x	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-0.69x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-136.36x	-398.86x	-421.28x	-	-	-
Total Equity+	-25.69M	-25.25M	-31.56M	10.12M	11.92M	7.51M	22.57M	11.75M	10.39M	8.08M
Equity Growth %	-	0.02%	-0.25%	1.32%	0.18%	-0.37%	2%	-0.48%	-0.12%	-0.22%
Book Value per Share	-2.16	-2.12	-2.65	0.88	0.98	0.41	0.86	0.41	0.36	0.21
Total Shareholders' Equity	-25.69M	-25.25M	-31.56M	10.12M	11.92M	7.51M	22.57M	11.75M	10.39M	8.08M
Common Stock	0	0	0	0	0	0	0	0	1K	1K
Retained Earnings	-29.42M	-30.62M	-41.81M	-52.12M	-62.91M	-70.24M	-82.43M	-95.5M	-104.39M	-113.93M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.4M	2.88M	7.4M	13.06M	11.44M	8.96M	41K	41K	41K	41K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.5M	-3.14M	-4.53M	-9.8M	-8.92M	-10.56M	-9.06M	-12.5M	-7.31M	-6.82M
Operating CF Margin %	-	-	-	-19.59%	-37.79%	-28.92%	-15.87%	-93.28%	-	-37.67%
Operating CF Growth %	-	0.1%	-0.44%	-1.16%	0.09%	-0.18%	0.14%	-0.38%	0.42%	0.07%
Net Income	-4.28M	-1.2M	-11.2M	-10.3M	-10.79M	-11.22M	-12.19M	-13.07M	-8.89M	-9.54M
Depreciation & Amortization	28K	35K	43K	54K	238K	63K	53K	64K	56K	46K
Stock-Based Compensation	366K	1.49M	4.88M	1.23M	1.48M	901K	1.86M	0	1.69M	2.56M
Deferred Taxes	0	22K	-324K	-41K	33K	0	-217K	174K	29K	14K
Other Non-Cash Items	576K	-3.84M	1.16M	-232K	-569K	46K	18K	2.17M	0	-5K
Working Capital Changes	-183K	353K	909K	-506K	691K	-351K	1.41M	-1.83M	-195K	112K
Change in Receivables	0	0	0	-725K	447K	23K	72K	-63K	246K	-126K
Change in Inventory	0	0	0	117K	341K	0	-72K	0	0	0
Change in Payables	227K	-298K	543K	-123K	-139K	-147K	74K	-149K	66K	49K
Cash from Investing+	-54K	-1.12M	1M	-4.07M	3.95M	-53K	-17K	-102K	-17K	-3K
Capital Expenditures	-54K	-41K	-51K	-68K	-40K	-53K	-17K	-47K	-17K	-3K
CapEx % of Revenue	-	-	-	0.14%	0.17%	0.15%	0.03%	0.35%	-	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-1.07M	1.05M	-4M	3.99M	0	0	-55K	0	0
Cash from Financing+	4.46M	7.22M	11.11M	9.62M	12.65M	4.05M	25.38M	13K	6.04M	4.48M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	238K	204K	3.58M	0	-580K	516K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.55M	-3.18M	-4.58M	-9.86M	-8.96M	-10.61M	-9.08M	-12.55M	-7.33M	-6.82M
FCF Margin %	-	-	-	-19.73%	-37.96%	-29.07%	-15.9%	-93.63%	-	-37.69%
FCF Growth %	-	0.1%	-0.44%	-1.16%	0.09%	-0.18%	0.14%	-0.38%	0.42%	0.07%
FCF per Share	-0.30	-0.27	-0.38	-0.86	-0.74	-0.58	-0.35	-0.44	-0.25	-0.18
FCF Conversion (FCF/Net Income)	0.82x	2.62x	0.40x	0.95x	0.83x	0.94x	0.74x	0.96x	0.82x	0.71x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	89K	2K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-101.86%	-97.98%	-115.46%	-81.04%	-76.17%	-80.3%	-103.34%
Gross Margin	-	-	-	100%	-89.83%	17.81%	34.68%	-23.13%	-	4.97%
Net Margin	-	-	-	-2060.8%	-4574.15%	-3072.88%	-2134.33%	-9754.48%	-	-5271.27%
Debt / Equity	-	-	-	-	0.03x	0.06x	0.01x	0.01x	0.04x	0.03x
Interest Coverage	-	-	-	-	-136.36x	-398.86x	-421.28x	-	-	-
FCF Conversion	0.82x	2.62x	0.40x	0.95x	0.83x	0.94x	0.74x	0.96x	0.82x	0.71x
Revenue Growth	-	-	-	-	-52.8%	54.66%	56.44%	-76.53%	-100%	-

Frequently Asked Questions

Growth & Financials

Entera Bio Ltd. (ENTX) reported $0.1M in revenue for fiscal year 2024.

Entera Bio Ltd. (ENTX) grew revenue by 0.0% over the past year. Growth has been modest.

Entera Bio Ltd. (ENTX) reported a net loss of $10.8M for fiscal year 2024.

Dividend & Returns

Entera Bio Ltd. (ENTX) has a return on equity (ROE) of -103.3%. Negative ROE indicates the company is unprofitable.

Entera Bio Ltd. (ENTX) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.